{"protocolSection":{"identificationModule":{"nctId":"NCT00894322","orgStudyIdInfo":{"id":"BCB110"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension","officialTitle":"A Two-Cohort, Single- and Repeat Dose Study to Examine the Pharmacokinetics, Tolerability, and Safety of Ready to Use Exenatide Once Weekly in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"statusVerifiedDate":"2015-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-04"},"primaryCompletionDateStruct":{"date":"2009-08","type":"ACTUAL"},"completionDateStruct":{"date":"2009-08","type":"ACTUAL"},"studyFirstSubmitDate":"2009-05-05","studyFirstSubmitQcDate":"2009-05-06","studyFirstPostDateStruct":{"date":"2009-05-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-04-16","resultsFirstSubmitQcDate":"2014-04-16","resultsFirstPostDateStruct":{"date":"2014-05-14","type":"ESTIMATED"},"dispFirstSubmitDate":"2013-03-06","dispFirstSubmitQcDate":"2013-04-24","dispFirstPostDateStruct":{"date":"2013-05-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-09-03","lastUpdatePostDateStruct":{"date":"2015-09-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"},"collaborators":[{"name":"Eli Lilly and Company","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study is designed to evaluate the pharmacokinetics, tolerability, and safety of exenatide once weekly suspension in both healthy subjects and in subjects with type 2 diabetes. The study will also evaluate efficacy in the type 2 diabetes patients. Development of this exenatide once weekly presentation would eliminate the need to reconstitute the product prior to use."},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"],"keywords":["diabetes","exenatide once weekly","Byetta","Amylin","Lilly"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":65,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1: Healthy Participants","type":"EXPERIMENTAL","description":"A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.","interventionNames":["Drug: exenatide once weekly"]},{"label":"Cohort 2: Diabetes Participants","type":"EXPERIMENTAL","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.","interventionNames":["Drug: exenatide once weekly"]},{"label":"Cohort 2: Diabetes Participants Placebo","type":"PLACEBO_COMPARATOR","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"exenatide once weekly","description":"subcutaneous injection, 10.0 mg, single injection","armGroupLabels":["Cohort 1: Healthy Participants"]},{"type":"DRUG","name":"exenatide once weekly","description":"subcutaneous injection, 2.0 mg, once a week for 12 weeks","armGroupLabels":["Cohort 2: Diabetes Participants"]},{"type":"OTHER","name":"Placebo","description":"subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks","armGroupLabels":["Cohort 2: Diabetes Participants Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 and the mean is presented below. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. AUC was measured in picograms \\* hours per milliliter (pg\\*hr/mL). Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA). AUC calculated using linear trapezoidal method from time x to time y; AUC (0-8h) and (0-tlast) are presented below. Pharmacokinetic (PK) evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] from Day 1 to Week 12 and had reliable PK data.","timeFrame":"Day 1, Week 12"},{"measure":"Maximum Concentration (Cmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 and the mean is presented below. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. Cmax was measured in picograms per milliliter (pg/mL). Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] from Day 1 to Week 12 for the evaluation of the PK characteristics of plasma exenatide and had reliable PK data. Cmax (0-8h) and (0-tlast) are presented below.","timeFrame":"Day 1, Week 12"},{"measure":"Time to Maximum Concentration (Tmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time(t) = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 an the mean is presented below. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. Tmax was measured in hours and Tmax (0-8h) and (0-tlast) are presented below. Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] and had reliable PK data.","timeFrame":"Day 1, Week 12"},{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Injection Site TEAEs, Serious Adverse Events (SAEs), Deaths, and Withdrawals Due to AEs in Cohort 1 and Cohort 2 in Intent to Treat (ITT) Population","description":"Treatment emergent (TE)=occurs during or after treatment with study drug. Adverse Event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Participants experiencing multiple episodes of a given AE are counted once. Injection site AEs: adverse events that existed prior to Day 1 and worsened after the first administration at Day 1, or occurred after the first administration at Day 1 through Week 12, or after Study Termination if considered by investigator to be clinically significant.","timeFrame":"Day 1 to Week12"},{"measure":"Number of Participants With Concomitant Medications in Cohort 1 and Cohort 2 in ITT Population","description":"Concomitant medications are defined as those medications received on or after the date of the first injection on Day 1, including prior medications that continued past Day 1 and new concomitant medications. Participants may be counted in more than one medication class and no more than once in each class. Categories by Anatomical Therapeutic Chemical (ATC) classification using the World Health Organization (WHO) Drug Dictionary version C1, 01 March 2009. As per protocol, all participants in Cohort 1 could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide.","timeFrame":"Day 1 to 12 weeks"},{"measure":"Mean Change From Baseline to End of Study in Sitting Diastolic and Systolic Blood Pressure in Cohorts 1 and 2 in ITT Population","description":"In Cohort 1, sitting blood pressures were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-11 (Visits 3-13), Week 12 (Visit 14), and at early termination. Blood pressures (diastolic and systolic) were measured in millimeters of mercury (mmHg). In Cohort 2, sitting blood pressures were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-10 (Visits 3-12), Week 11 (Visit 15), Week 12 (Visit 16) and at early termination. Baseline was defined as last measurement prior to first injection of study drug.","timeFrame":"Day 1 to Week 12"},{"measure":"Mean Change From Baseline to End of Study in Sitting Heart Rate in Cohorts 1 and 2 in ITT Population","description":"In Cohort 1, sitting heart rates were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-11 (Visits 3-13), Week 12 (Visit 14), and at early termination. Heart rate was measured in beats per minute (bpm). In Cohort 2, sitting heart rates were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-10 (Visits 3-12), Week 11 (Visit 15), Week 12 (Visit 16) and at early termination. Baseline was defined as last measurement prior to first injection of study drug.","timeFrame":"Day 1 to Week 12"},{"measure":"Number of Participants With Hematology and Serum Chemistry Laboratory Values of Potential Clinical Importance in Cohorts 1 and 2 in ITT Population","description":"Abbreviations: Upper Limit of Normal (ULN); milligram per deciliter (mg/dL); units per liter (U/L); micro liters (µL); creatine kinase (CK); gamma-glutamyltransferase (G-GT). Normal ranges = Hematocrit: 40.6-52.3% (male), 35.3-47.0 (female); Platelets 155-361\\*10\\^3/µL(male/female); Calcium: 8.6-10.4 mg/dL (male/female); CK: 43-350 U/L (male), 28-207 U/L (female); G-GT: 7-62 U/L (male/female); Glucose 73-105 mg/dL (male/female); Lipase 14-70 U/L (male/female); Uric acid: 3.5-7.8 mg/dL (male), 2.3-5.9 mg/dL (female). Blood samples for laboratories were collected at screening, Day 1, Weeks 4, 8, 12 or early termination. Value for potential clinical importance is presented in each category presented below.","timeFrame":"Day 1 to Week 12"},{"measure":"Antibody Titers for Participants With Treatment Emergent Positive Antibodies to Exenatide in Participants Who Received Exenatide in Cohorts 1 and 2","description":"Serum titers of antibodies to exenatide were evaluated using a validated enzyme-linked immunosorbent assay (Covance Method No. ELISA-0308). Positive antibody to exenatide titer: observed at the indicated visit following a negative or missing titer at baseline, or a positive titer that has increased by at least 3 dilutions at the indicated visit from a detectable baseline. Baseline=Day 1. Negative titers were assigned a value of 1 in order to calculate geometric mean. Geometric mean of reportable titers, by study week, are presented below.","timeFrame":"Day 1 to Week 12"},{"measure":"Area Under the Curve (AUC) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. AUC was measured in picograms \\* hours per milliliter (pg\\*hr/mL). Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA). AUC calculated using linear trapezoidal method from time x to time y; AUC (0-6h) measured at Week 10, AUC (0-168h) steady state measured between Weeks 10 and 11, and AUC (0-tlast) for time interval between Weeks 10 and 12 (approximately336 hours) are presented below. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","timeFrame":"Week 10-11; Weeks 10 - 12"},{"measure":"Average Exenatide Concentration (Cave) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. Cave(0-168h) and Cave(0-tlast) was the time-weighted mean concentration over the sampling period from time x to time y corresponding to AUC (0-168h), and AUC (0-tlast), respectively. Cave was measured in picograms per milliliter (pg/mL). Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","timeFrame":"Week 10 - Week 11; Week 10 - Week 12"},{"measure":"Maximum Concentration (Cmax) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. Cmax was measured in pg/mL. Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA). Cmax summarized at 0-6 h at Week 10, 0-168 h at Weeks 10-11, and 0-tlast at Weeks 10-12. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","timeFrame":"Week 10, Weeks 10-11, Weeks 10-12"},{"measure":"Time to Maximum Concentration (Tmax) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. Tmax was measured in hours (h). Exenatide was measured using a validated ELISA. Tmax summarized at 0-6 h at Week 10, 0-168 h at Weeks 10-11, and 0-tlast at Weeks 10-12. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","timeFrame":"Week 10, Weeks 10-11, Weeks 10-12"}],"secondaryOutcomes":[{"measure":"AUC (0 Hour to 168 Hour) for 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. AUC (0-168 h) data represents average concentration rather than maximum concentration. Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). AUC calculated using linear trapezoidal method from time x to time y and measured in pg\\*h/mL. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","timeFrame":"Day 1 to Week 1"},{"measure":"Average Exenatide Concentration (Cave) of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1. At all visits following the single dose, a single blood sample was collected for assessment of exenatide concentrations. Cave(0-168h) was the time-weighted mean concentration over the sampling period from time x to time y corresponding to AUC (0-168h) and was measured in picograms per milliliter (pg/mL). Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] from Day 1 to Week 12 and had reliable PK data.","timeFrame":"Day 1 to Week 1"},{"measure":"Least Square Mean Change From Baseline in Hemoglobin A1c (HbA1c) to Week 12 in Participants With Diabetes (Cohort 2) in the ITT Population","description":"HbA1c was measured as a percent of hemoglobin at screening, Day 1, Weeks 4, 8, 12 or early termination. Last observation carried forward (LOCF) was applied to estimate missing values at post baseline timepoints. Baseline=Day 1, last measurement prior to first dose of study drug.","timeFrame":"Day 1 to Week 12"},{"measure":"Number of Participants Achieving HbA1c Less Than Equal to (<=) 6.5% and Less Than (<) 7% at Week 12 in Participants With Diabetes (Cohort 2) in the ITT Population","description":"HbA1c was measured as a percent of hemoglobin at screening, Day 1, Weeks 4, 8, 12 or early termination. LOCF was applied to estimate missing values at post baseline timepoints. Baseline=Day 1, last measurement prior to first dose of study drug.","timeFrame":"Week 12"},{"measure":"Mean Change From Baseline at Week 12 in Body Weight in Participants With Diabetes (Cohort 2) in the ITT Population","description":"Body weight was measured in kilograms (kg). Baseline was Day 1, last measurement prior to first dose of study drug. Body weight was measured at screening, Day 1, Weeks 4, 8, 12 or early termination and the LOCF approach was applied to estimate missing value at each post baseline timepoint.","timeFrame":"Baseline, Week 12"},{"measure":"Mean Change From Baseline at Week 12 in Fasting Plasma Glucose in Participants With Diabetes (Cohort 2) for the ITT Population","description":"Baseline was the last measurement at the screening visit. Fasting plasma glucose (FPG) was measured at screening, Day 1, Weeks 2, 4, 6, 8, 12, or early termination and reported in milligrams per deciliter (mg/dL).","timeFrame":"Baseline, Week 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nCohort 1:\n\n* Is 19 to 65 years old\n* Has a body mass index (BMI) of 23 kg/m2 to 35 kg/m2, inclusive, at study start\n\nCohort 2:\n\n* Is 19 to 75 years old\n* Has been diagnosed with type 2 diabetes mellitus\n* Has HbA1c of 7.1% to 10.0%, inclusive, at study start\n* Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at study start\n* Has been treated with diet and exercise alone or with a stable regimen of metformin, a TZD, or a combination of metformin and a TZD, for a minimum of 2 months prior to study start\n* Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start:\n\n  * Hormone replacement therapy (female subjects)\n  * Oral contraceptives (female subjects)\n  * Antihypertensive agents\n  * Lipid-lowering agents\n  * Thyroid replacement therapy\n  * Antidepressant agents\n\nExclusion Criteria:\n\nCohort 1:\n\n* Has a personal history of diabetes mellitus (including impaired glucose tolerance, impaired fasting glucose, or gestational diabetes)\n* Has received any investigational drug within 30 days (or 5 half-lives of the investigational drug, whichever is greater) prior to study start\n* Has ever been exposed to exenatide (BYETTA, exenatide once weekly, or any other formulation of exenatide) or any GLP 1 analog\n\nCohort 2:\n\n* Has received any investigational drug within 30 days (or 5 half-lives of the investigational drug, whichever is greater) prior to study start\n* Has ever been exposed to exenatide (BYETTA, exenatide once weekly, or any other formulation of exenatide) or any GLP 1 analog\n* Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment-excluded medications:\n\n  * Any DPP-4 inhibitor or sulfonylurea (SU) within 3 months prior to study start\n  * Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days prior to study start\n  * Insulin within 2 weeks prior to study start or for more than 1 week within 3 months prior to study start\n  * Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption\n  * Prescription or over-the-counter weight loss medications within 3 months prior to study start","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Vice President, Clinical Development","affiliation":"Amylin Pharmaceuticals, LLC.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Lincoln","state":"Nebraska","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}}]},"referencesModule":{"seeAlsoLinks":[{"label":"CSR\\_Synopsis","url":"http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3660&filename=Study_Synopsis.pdf"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Enrolled participants in Cohort 1 were treated on Day 1 only. Enrolled participants who were in Cohort 2 were randomized to one of 2 treatment arms (exenatide or placebo) and were treated for 12 weeks.","recruitmentDetails":"Healthy participants were enrolled in Cohort 1 while participants with type 2 diabetes mellitus were enrolled in Cohort 2.","groups":[{"id":"FG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"FG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of 2 mg exenatide suspension for 12 weeks. Study medication was administered weekly."},{"id":"FG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent to treat (ITT) population. All randomized participants who received at least 1 dose of study medication were included in the ITT population. Totals presented are for only Cohort 2 (35 participants), not for both Cohort 1 and 2.","groups":[{"id":"BG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"BG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of 2 mg exenatide suspension for 12 weeks. Study medication was administered weekly."},{"id":"BG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"65"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41.2","spread":"14.4"},{"groupId":"BG001","value":"52.7","spread":"11.6"},{"groupId":"BG002","value":"52.0","spread":"9.3"},{"groupId":"BG003","value":"52.4","spread":"10.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"23"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"42"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"53"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}]},{"title":"Native American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"65"}]}]}]},{"title":"Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"85.9","spread":"15.5"},{"groupId":"BG001","value":"104.9","spread":"23.2"},{"groupId":"BG002","value":"104.4","spread":"20.3"},{"groupId":"BG003","value":"104.7","spread":"22.0"}]}]}]},{"title":"Body Mass Index (BMI)","description":"BMI was measured in kilograms (kg) of body weight per meter (m) of height, squared.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.5","spread":"3.5"},{"groupId":"BG001","value":"35.3","spread":"6.7"},{"groupId":"BG002","value":"34.9","spread":"4.9"},{"groupId":"BG003","value":"35.1","spread":"6.1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 and the mean is presented below. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. AUC was measured in picograms \\* hours per milliliter (pg\\*hr/mL). Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA). AUC calculated using linear trapezoidal method from time x to time y; AUC (0-8h) and (0-tlast) are presented below. Pharmacokinetic (PK) evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] from Day 1 to Week 12 and had reliable PK data.","populationDescription":"PK evaluable population was analyzed. n in categories below = number of ITT participants with PK evaluable data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pg*h/mL","timeFrame":"Day 1, Week 12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"classes":[{"title":"AUC (0-8h), n=30","categories":[{"measurements":[{"groupId":"OG000","value":"125.6","spread":"41.16"}]}]},{"title":"AUC (0-Week 12), n=30","categories":[{"measurements":[{"groupId":"OG000","value":"147220.2","spread":"24000.04"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration (Cmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 and the mean is presented below. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. Cmax was measured in picograms per milliliter (pg/mL). Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] from Day 1 to Week 12 for the evaluation of the PK characteristics of plasma exenatide and had reliable PK data. Cmax (0-8h) and (0-tlast) are presented below.","populationDescription":"PK evaluable population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pg/mL","timeFrame":"Day 1, Week 12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"classes":[{"title":"Cmax 0 hour to 8 hours","categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":"8.33"}]}]},{"title":"Cmax 0 hour to Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"331.2","spread":"46.90"}]}]}]},{"type":"PRIMARY","title":"Time to Maximum Concentration (Tmax) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time(t) = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1 an the mean is presented below. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. Tmax was measured in hours and Tmax (0-8h) and (0-tlast) are presented below. Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] and had reliable PK data.","populationDescription":"PK evaluable population. n=number of participants who had reliable PK data available to be evaluated.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"hours","timeFrame":"Day 1, Week 12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"classes":[{"title":"Tmax (0 to 8 hours), n=27","categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"0.43"}]}]},{"title":"Tmax (0 hour to Week 12), n=30","categories":[{"measurements":[{"groupId":"OG000","value":"998.1","spread":"67.60"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Injection Site TEAEs, Serious Adverse Events (SAEs), Deaths, and Withdrawals Due to AEs in Cohort 1 and Cohort 2 in Intent to Treat (ITT) Population","description":"Treatment emergent (TE)=occurs during or after treatment with study drug. Adverse Event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Participants experiencing multiple episodes of a given AE are counted once. Injection site AEs: adverse events that existed prior to Day 1 and worsened after the first administration at Day 1, or occurred after the first administration at Day 1 through Week 12, or after Study Termination if considered by investigator to be clinically significant.","populationDescription":"ITT population included all participants treated with at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 to Week12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"OG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"9"}]}]},{"title":"Injection Site TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"7"}]}]},{"title":"Withdrawal due to AE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"SAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Death","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Concomitant Medications in Cohort 1 and Cohort 2 in ITT Population","description":"Concomitant medications are defined as those medications received on or after the date of the first injection on Day 1, including prior medications that continued past Day 1 and new concomitant medications. Participants may be counted in more than one medication class and no more than once in each class. Categories by Anatomical Therapeutic Chemical (ATC) classification using the World Health Organization (WHO) Drug Dictionary version C1, 01 March 2009. As per protocol, all participants in Cohort 1 could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide.","populationDescription":"ITT population included all participants treated with at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 to 12 weeks","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"OG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"11"}]}]}]},{"type":"SECONDARY","title":"AUC (0 Hour to 168 Hour) for 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. AUC (0-168 h) data represents average concentration rather than maximum concentration. Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). AUC calculated using linear trapezoidal method from time x to time y and measured in pg\\*h/mL. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","populationDescription":"PK evaluable population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pg*h/mL","timeFrame":"Day 1 to Week 1","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3269.6","spread":"1661.45"}]}]}]},{"type":"SECONDARY","title":"Average Exenatide Concentration (Cave) of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population","description":"Cohort 1: Blood samples for the assessment of plasma exenatide were collected at time = -15, 60, 90, 120, 180, 240, 360, and 480 minutes relative to study medication injection at time = 0 on Day 1. At all visits following the single dose, a single blood sample was collected for assessment of exenatide concentrations. Cave(0-168h) was the time-weighted mean concentration over the sampling period from time x to time y corresponding to AUC (0-168h) and was measured in picograms per milliliter (pg/mL). Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements \\[not less than (\\<) lower limits of quantification (LLOQ)\\] from Day 1 to Week 12 and had reliable PK data.","populationDescription":"PK evaluable population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pg/mL","timeFrame":"Day 1 to Week 1","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":"7.53"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to End of Study in Sitting Diastolic and Systolic Blood Pressure in Cohorts 1 and 2 in ITT Population","description":"In Cohort 1, sitting blood pressures were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-11 (Visits 3-13), Week 12 (Visit 14), and at early termination. Blood pressures (diastolic and systolic) were measured in millimeters of mercury (mmHg). In Cohort 2, sitting blood pressures were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-10 (Visits 3-12), Week 11 (Visit 15), Week 12 (Visit 16) and at early termination. Baseline was defined as last measurement prior to first injection of study drug.","populationDescription":"ITT population included all participants treated with at least one dose of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Week 12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"OG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"Diastolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"7.05"},{"groupId":"OG001","value":"4.6","spread":"8.81"},{"groupId":"OG002","value":"6.8","spread":"7.81"}]}]},{"title":"Systolic Blood Pressure","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"9.59"},{"groupId":"OG001","value":"-8.4","spread":"14.15"},{"groupId":"OG002","value":"-1.7","spread":"12.47"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline to End of Study in Sitting Heart Rate in Cohorts 1 and 2 in ITT Population","description":"In Cohort 1, sitting heart rates were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-11 (Visits 3-13), Week 12 (Visit 14), and at early termination. Heart rate was measured in beats per minute (bpm). In Cohort 2, sitting heart rates were obtained at Screening (Visit 1), Day 1 (Visit 2), Weeks 1-10 (Visits 3-12), Week 11 (Visit 15), Week 12 (Visit 16) and at early termination. Baseline was defined as last measurement prior to first injection of study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"bpm","timeFrame":"Day 1 to Week 12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"OG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"9.38"},{"groupId":"OG001","value":"-5.4","spread":"8.10"},{"groupId":"OG002","value":"-9.1","spread":"7.03"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Hematology and Serum Chemistry Laboratory Values of Potential Clinical Importance in Cohorts 1 and 2 in ITT Population","description":"Abbreviations: Upper Limit of Normal (ULN); milligram per deciliter (mg/dL); units per liter (U/L); micro liters (µL); creatine kinase (CK); gamma-glutamyltransferase (G-GT). Normal ranges = Hematocrit: 40.6-52.3% (male), 35.3-47.0 (female); Platelets 155-361\\*10\\^3/µL(male/female); Calcium: 8.6-10.4 mg/dL (male/female); CK: 43-350 U/L (male), 28-207 U/L (female); G-GT: 7-62 U/L (male/female); Glucose 73-105 mg/dL (male/female); Lipase 14-70 U/L (male/female); Uric acid: 3.5-7.8 mg/dL (male), 2.3-5.9 mg/dL (female). Blood samples for laboratories were collected at screening, Day 1, Weeks 4, 8, 12 or early termination. Value for potential clinical importance is presented in each category presented below.","populationDescription":"ITT population included all participants treated with at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 to Week 12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"OG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"Hematocrit low <36%","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Platelets high <75 to >500*10^3/µ/L","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Calcium high <8 to >11 mg/dL","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"CK high >3*ULN","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"G-GT high >3*ULN in U/L","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Glucose low <50 to > 450 mg/dL","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Lipase high >3*ULN in U/L","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Uric Acid high >8.0 mg/dL","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Antibody Titers for Participants With Treatment Emergent Positive Antibodies to Exenatide in Participants Who Received Exenatide in Cohorts 1 and 2","description":"Serum titers of antibodies to exenatide were evaluated using a validated enzyme-linked immunosorbent assay (Covance Method No. ELISA-0308). Positive antibody to exenatide titer: observed at the indicated visit following a negative or missing titer at baseline, or a positive titer that has increased by at least 3 dilutions at the indicated visit from a detectable baseline. Baseline=Day 1. Negative titers were assigned a value of 1 in order to calculate geometric mean. Geometric mean of reportable titers, by study week, are presented below.","populationDescription":"Only participants who received exenatide were analyzed (no placebo-treated participants were included). N=number of participants in each treatment at each visit and n= number of participants with reportable titers at the visit. Last visit=last visit with reportable titers.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Reportable Titers","timeFrame":"Day 1 to Week 12","groups":[{"id":"OG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose."},{"id":"OG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"23"}]}],"classes":[{"title":"Week 2, N=30, 23; n=4, 1","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"0.0"},{"groupId":"OG001","value":"25.0","spread":"NA","comment":"Only 1 participant with reportable titer so SE cannot be calculated."}]}]},{"title":"Week 4, N=30, 23; n=14, 10","categories":[{"measurements":[{"groupId":"OG000","value":"394.6","spread":"204.4"},{"groupId":"OG001","value":"202.6","spread":"109.2"}]}]},{"title":"Week 6, N=30, 23; n=0, 15","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No reportable titers (n=0) available for this week in this treatment group so mean (SE) are not applicable (n/a)"},{"groupId":"OG001","value":"295.9","spread":"129.9"}]}]},{"title":"Week 8, N=29, 23; n=22,15","categories":[{"measurements":[{"groupId":"OG000","value":"300.7","spread":"118.0"},{"groupId":"OG001","value":"561.4","spread":"186.4"}]}]},{"title":"Week 10, N=29, 23; n=0,15","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No reportable titers (n=0) available for this week in this treatment group so mean (SE) are not applicable (n/a)"},{"groupId":"OG001","value":"453.0","spread":"190.9"}]}]},{"title":"Last visit, N=30, 23; n=20, 15","categories":[{"measurements":[{"groupId":"OG000","value":"202.6","spread":"63.0"},{"groupId":"OG001","value":"625.0","spread":"294.5"}]}]}]},{"type":"SECONDARY","title":"Least Square Mean Change From Baseline in Hemoglobin A1c (HbA1c) to Week 12 in Participants With Diabetes (Cohort 2) in the ITT Population","description":"HbA1c was measured as a percent of hemoglobin at screening, Day 1, Weeks 4, 8, 12 or early termination. Last observation carried forward (LOCF) was applied to estimate missing values at post baseline timepoints. Baseline=Day 1, last measurement prior to first dose of study drug.","populationDescription":"ITT population included all participants treated with at least one dose of study drug. This analysis was only done in Cohort 2 so the ITT population of Cohort 2 was available for analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent of hemoglobin","timeFrame":"Day 1 to Week 12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG001","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":"0.179"},{"groupId":"OG001","value":"0.08","spread":"0.231"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0013","pValueComment":"Treatment group and HbA1c stratum at screening were factors. Placebo was reference group.","statisticalMethod":"ANOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.50","ciUpperLimit":"-0.40","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.269"}]},{"type":"SECONDARY","title":"Number of Participants Achieving HbA1c Less Than Equal to (<=) 6.5% and Less Than (<) 7% at Week 12 in Participants With Diabetes (Cohort 2) in the ITT Population","description":"HbA1c was measured as a percent of hemoglobin at screening, Day 1, Weeks 4, 8, 12 or early termination. LOCF was applied to estimate missing values at post baseline timepoints. Baseline=Day 1, last measurement prior to first dose of study drug.","populationDescription":"ITT population included all participants treated with at least one dose of study drug. Only those ITT participants in Cohort 2 were analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG001","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"Baseline HbA1c >= 7%","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"12"}]}]},{"title":"Week 12 HbA1c <= 6.5%","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"}]}]},{"title":"Week 12 HbA1c <7%","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0033","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"Adjusted for HbA1c strata at screening."}]},{"type":"SECONDARY","title":"Mean Change From Baseline at Week 12 in Body Weight in Participants With Diabetes (Cohort 2) in the ITT Population","description":"Body weight was measured in kilograms (kg). Baseline was Day 1, last measurement prior to first dose of study drug. Body weight was measured at screening, Day 1, Weeks 4, 8, 12 or early termination and the LOCF approach was applied to estimate missing value at each post baseline timepoint.","populationDescription":"ITT population included all participants treated with at least one dose of study drug. Only Cohort 2 was analyzed for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG001","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.41","spread":"0.558"},{"groupId":"OG001","value":"-0.39","spread":"0.717"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Least square mean (LS) mean, 95% confidence interval (CI) and p-value calculated for the changes in weight from baseline in participants in cohort 2 treated with exenatide with placebo as reference group.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2285","statisticalMethod":"ANOVA","statisticalComment":"treatment group and HbA1c stratum at screening were factors.","paramType":"LS Mean Difference","paramValue":"-1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.73","ciUpperLimit":"0.68","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.835"}]},{"type":"SECONDARY","title":"Mean Change From Baseline at Week 12 in Fasting Plasma Glucose in Participants With Diabetes (Cohort 2) for the ITT Population","description":"Baseline was the last measurement at the screening visit. Fasting plasma glucose (FPG) was measured at screening, Day 1, Weeks 2, 4, 6, 8, 12, or early termination and reported in milligrams per deciliter (mg/dL).","populationDescription":"ITT population included all participants treated with at least one dose of study drug. Only participants in Cohort 2 were evaluated for this Outcome Measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."},{"id":"OG001","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32","spread":"9.9"},{"groupId":"OG001","value":"8","spread":"11.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0035","statisticalMethod":"ANOVA","statisticalComment":"treatment group and HbA1c stratum at screening were factors.","paramType":"LS Mean Difference","paramValue":"-40.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-66.5","ciUpperLimit":"-14.3","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"12.8"}]},{"type":"PRIMARY","title":"Area Under the Curve (AUC) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. AUC was measured in picograms \\* hours per milliliter (pg\\*hr/mL). Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA). AUC calculated using linear trapezoidal method from time x to time y; AUC (0-6h) measured at Week 10, AUC (0-168h) steady state measured between Weeks 10 and 11, and AUC (0-tlast) for time interval between Weeks 10 and 12 (approximately336 hours) are presented below. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","populationDescription":"PK evaluable population was analyzed. In categories below, n = number of ITT participants with PK evaluable data. Note: Placebo-treated participants not included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pg*hr/mL","timeFrame":"Week 10-11; Weeks 10 - 12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"classes":[{"title":"AUC (0-6h) at Week 10, n=18","categories":[{"measurements":[{"groupId":"OG000","value":"1535.3","spread":"232.40"}]}]},{"title":"AUC (0-168h) at Weeks 10-11, n=18","categories":[{"measurements":[{"groupId":"OG000","value":"49100.2","spread":"6796.56"}]}]},{"title":"AUC (0-tlast) at Weeks 10-12, n=17","categories":[{"measurements":[{"groupId":"OG000","value":"101615.0","spread":"12927.42"}]}]}]},{"type":"PRIMARY","title":"Average Exenatide Concentration (Cave) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. At all visits following the single injection, a single blood sample was collected for assessment of exenatide concentrations. Cave(0-168h) and Cave(0-tlast) was the time-weighted mean concentration over the sampling period from time x to time y corresponding to AUC (0-168h), and AUC (0-tlast), respectively. Cave was measured in picograms per milliliter (pg/mL). Exenatide concentration was measured using a validated enzyme-linked immunosorbent assay (ELISA). PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","populationDescription":"PK evaluable population was analyzed. In categories below, n = number of ITT participants with PK evaluable data. Note: Placebo-treated participants not included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pg/mL","timeFrame":"Week 10 - Week 11; Week 10 - Week 12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"classes":[{"title":"Cave at Weeks 10-11; n=18","categories":[{"measurements":[{"groupId":"OG000","value":"292.7","spread":"40.52"}]}]},{"title":"Cave at Weeks 10-12; n=17","categories":[{"measurements":[{"groupId":"OG000","value":"302.4","spread":"38.47"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration (Cmax) for 2 mg Exenatide (Cohort 2) in Participants With Diabetes in the Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. Cmax was measured in pg/mL. Exenatide was measured using a validated enzyme-linked immunosorbent assay (ELISA). Cmax summarized at 0-6 h at Week 10, 0-168 h at Weeks 10-11, and 0-tlast at Weeks 10-12. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","populationDescription":"PK evaluable population was analyzed. In categories below, n = number of ITT participants with PK evaluable data. Note: Placebo-treated participants not included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pg/mL","timeFrame":"Week 10, Weeks 10-11, Weeks 10-12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"classes":[{"title":"Cmax at 0-6 h Week 10; n=18","categories":[{"measurements":[{"groupId":"OG000","value":"304.9","spread":"47.39"}]}]},{"title":"Cmax at 0-168 h Weeks 10=11; n=18","categories":[{"measurements":[{"groupId":"OG000","value":"362.6","spread":"50.86"}]}]},{"title":"Cmax at 0-tlast Weeks 10-12; n=17","categories":[{"measurements":[{"groupId":"OG000","value":"410.5","spread":"53.27"}]}]}]},{"type":"PRIMARY","title":"Time to Maximum Concentration (Tmax) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in Pharmacokinetic Evaluable Population","description":"Cohort 2: Blood samples for the assessment of plasma exenatide were collected on Day 1, Weeks 2, 4, 6, 8, and 10. At Week 10, blood samples were collected at time = -15, 60, 90, 120, 180, 240, and 360 minutes relative to study medication injection at time = 0. Tmax was measured in hours (h). Exenatide was measured using a validated ELISA. Tmax summarized at 0-6 h at Week 10, 0-168 h at Weeks 10-11, and 0-tlast at Weeks 10-12. PK evaluable population consisted of all ITT participants who had at least 4 detectable plasma exenatide measurements (not \\< LLOQ) from Day 1 to Week 12 and had reliable PK data.","populationDescription":"PK evaluable population was analyzed. In categories below, n = number of ITT participants with PK evaluable data. Note: Placebo-treated participants not included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Error","unitOfMeasure":"hours","timeFrame":"Week 10, Weeks 10-11, Weeks 10-12","groups":[{"id":"OG000","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"classes":[{"title":"Tmax 0-6 h Week; n=18","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.20"}]}]},{"title":"Tmax 0-168 h Weeks 10-11; n=18","categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":"13.96"}]}]},{"title":"Tmax 0-tlast Weeks 10-12; n=17","categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":"26.01"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Day 1 to Week 12","eventGroups":[{"id":"EG000","title":"Cohort 1 Exenatide 10 mg","description":"A single 10-mg dose of exenatide once weekly suspension was given to healthy participants via 3 subcutaneous (SC) injections at Day 1. At the discretion of the investigator, participants could receive up to 2 anti-emetic medications approximately 30 minutes prior to the exenatide once weekly suspension dose.","seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":26,"otherNumAtRisk":30},{"id":"EG001","title":"Cohort 2 Exenatide 2 mg","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11).","seriousNumAffected":0,"seriousNumAtRisk":23,"otherNumAffected":22,"otherNumAtRisk":23},{"id":"EG002","title":"Cohort 2 Placebo","description":"On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, a thiazolidinedione (TZD), or a combination of metformin or a TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks. Study medication was administered weekly from Visit 2 (Day 1) to Visit 15 (Week 11).","seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":9,"otherNumAtRisk":12}],"seriousEvents":[{"term":"Infected Skin Ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]}],"otherEvents":[{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Corneal erosion","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Photophobia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":4,"numAtRisk":23},{"groupId":"EG002","numAffected":2,"numAtRisk":12}]},{"term":"Dry Mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Hyperchlorhydria","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":5,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Feeling jittery","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Infection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30},{"groupId":"EG001","numAffected":12,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Injection site hematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":30},{"groupId":"EG001","numAffected":9,"numAtRisk":23},{"groupId":"EG002","numAffected":6,"numAtRisk":12}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30},{"groupId":"EG001","numAffected":5,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Injection site papule","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":30},{"groupId":"EG001","numAffected":11,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Injection site warmth","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Edema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Vessel puncture site hematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Vaginitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Blister","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Joint sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":5,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Petechiae","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"AstraZeneca","organization":"Clinical Trial Transparency","email":"Clinical.Trial.Transparency@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D003920","term":"Diabetes Mellitus"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]}},"hasResults":true}